Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) accounts for approximately 90% of liver cancer cases. Sorafenib, the first drug to demonstrate survival benefits for advanced HCC, was validated through the SHARP randomized clinical trial (RCT). While RCTs are essential for assessing new therapies, real-wo...
Saved in:
| Main Authors: | Angélica Richart Csipak, Leonardo G. da Fonseca, Rossana Verónica Mendoza López, Maria Del Pilar Estevez-Diz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/11/500 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
by: Young Eun Chon, et al.
Published: (2025-01-01) -
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01) -
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
by: Wenjun Meng, et al.
Published: (2024-12-01) -
Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
by: Tzu-Rong Peng, et al.
Published: (2022-01-01) -
Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01)